Moderna Stock Plunges 14.52% Amid FDA Regulatory Shakeup

On March 31, 2025, Moderna's stock experienced a significant drop of 14.52% in pre-market trading.

Moderna's stock price plummeted following a shakeup at the FDA. The sudden change in regulatory dynamics has raised concerns among investors about the future approval and distribution of Moderna's products, particularly its COVID-19 vaccine. The FDA's recent actions have led to uncertainty, causing a sell-off in Moderna's shares as investors reassess the company's prospects in the face of potential regulatory hurdles.

This development comes at a critical time for Moderna, as the company continues to navigate the evolving landscape of the pharmaceutical industry. The FDA's decisions can have a profound impact on the approval and marketability of new drugs and vaccines, making regulatory stability a key factor in investor confidence. Moderna's ability to adapt to these changes and maintain its position in the market will be closely watched in the coming months.